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Abstract
The reporting of the first draft of the human genome in 2000 brought with it much hope for the future in what
was felt as a paradigm shift toward improved health outcomes. Indeed, we have now mapped the majority of
variation across human populations with landmark projects such as 1000 Genomes; in cancer, we have catalogued
mutations across the primary carcinomas; whilst, for other diseases, we have identified the genetic variants with
strongest association. Despite this, we are still awaiting the genetic revolution in healthcare to materialise and
translate itself into the health benefits for which we had hoped. A major problem we face relates to our underestimation
of the complexity of the genome, and that of biological mechanisms, generally. Fixation on DNA sequence alone and a
‘rigid’ mode of thinking about the genome has meant that the folding and structure of the DNA molecule —and how
these relate to regulation— have been underappreciated. Projects like ENCODE have additionally taught us that
regulation at the level of RNA is just as important as that at the spatiotemporal level of chromatin.
In this review, we chart the course of the major advances in the biomedical sciences in the era pre- and post the
release of the first draft sequence of the human genome, taking a focus on technology and how its development
has influenced these. We additionally focus on gene editing via CRISPR/Cas9 as a key technique, in particular its
use in the context of complex biological mechanisms. Our aim is to shift the mode of thinking about the genome to
that which encompasses a greater appreciation of the folding of the DNA molecule, DNA- RNA/protein interactions,
and how these regulate expression and elaborate disease mechanisms.
Through the composition of our work, we recognise that technological improvement is conducive to a greater
understanding of biological processes and life within the cell. We believe we now have the technology at our
disposal that permits a better understanding of disease mechanisms, achievable through integrative data analyses. Finally,
only with greater understanding of disease mechanisms can techniques such as gene editing be faithfully conducted.
Keywords: Gene editing, Genomic complexity, Genome, Transcriptome, Epigenome, Sequencing technology development,
Complex genetics, CRISPR, Integrated omics
Background
Life is more complex than we had previously thought. We
have mapped the entire healthy human genome [1, 2] but
many unanswered questions and challenges remain in
terms of the genome’s relationship with disease [3–5].
Indeed, when former President Clinton exited the White
House to announce the first draft of the human genome,
his words were met with the belief that we had made a
paradigm shift toward a better understanding of human
disease, with DNA being likened by Clinton to “the lan-
guage in which God created life” [6]. Fast approaching
20 years since that announcement from the White House
in June, 2000, and it may feel as if the fanfare that
accompanied the occasion was premature. Perspective is a
luxury, though, and although it can feel like research in
the biological and medical sciences (‘biomedical sciences’)
since that time has been slower than expected, we have
nevertheless made huge progress, even looking far beyond
the genome.
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Indeed, international landmark projects such as the en-
cyclopaedia of DNA elements in the human genome
(ENCODE) [7] and functional annotation of the mamma-
lian genome (FANTOM) [8] have shone much light on
life’s complexity through their studies on the transcrip-
tome and epigenome, confirming the earliest conclusions
by Lander and colleagues in their summary of the first hu-
man genome sequence [2]: “The potential numbers of dif-
ferent proteins and protein–protein interactions are vast,
and their actual numbers cannot readily be discerned from
the genome sequence. Elucidating such system-level proper-
ties presents one of the great challenges for modern
biology”. The challenge to which Lander alludes is still
very much felt today, and these words are being confirmed
as we delve even further into disease mechanisms and
pathobiology.
The genome
Projects like ENCODE [7] and FANTOM [8] provide
evidence that it’s no longer sufficient to think of DNA as
the Holy Grail. Despite this, much focus and attention is
still given to the genome and its usage in tackling dis-
ease through ‘genomic medicine’ and ‘personalized medi-
cine’ [9–12]. However, there is doubt [13–15], and it has
become apparent that simply knowing the sequence of
DNA is not enough to fully understand disease and to
drive us forward.
To take the focus completely away from the genome is
to diminish its importance in disease, and we are not
implying that we should ever ignore what the genome
may be telling us; yet, it is clear that reading just the
genomic sequence is not enough. Further evidence of
this comes from projects such as The Cancer Genome
Atlas (TCGA) [16] and International Cancer Genome
Consortium (ICGC) [17], who, combined, now have the
whole genome sequence of thousands of tumour-normal
pairs across multiple cancers. Such information allows
us to catalogue the main genes implicated in each cancer
[18–21] but leaves us far from completely understanding
the underlying mechanisms that are at play. For ex-
ample, genome-wide association studies (GWAS) have
for many years done very well at finding strong associa-
tions between SNPs and diseases of all types [22]. How-
ever, it is important to realise that the majority (roughly
95%) of statistically significant GWAS SNPs are not
found in coding regions and instead lie in regions of
regulatory DNA [23], a truth that leaves us to merely
hypothesise on what the underlying mechanisms may be
(see Table 1 for an example in breast cancer). Regret-
fully, GWAS have also been difficult to replicate [24–
26], with Colhoun and colleagues specifically alluding to
the complexity of disease traits as an issue [27]. Other
issues include poor study design in both the initial and
replication study as the chief causes, including small
sample sizes and insufficient power, lack of comparability
between cases and controls, and ignoring underlying
population structure [28]. As of writing (March, 2017), the
The National Human Genome Research Institute
(NHGRI) [29] lists 35,329 GWAS hits reaching
genome-wide significance, spanning > 1700 diseases or
phenotypes, ranging from severe acne to World class en-
durance athleticism, variant Creutzfeldt-Jakob Disease
(vCJD) to Sjögren’s syndrome, etc. Despite these large ef-
forts, our knowledge of the genetic basis of many traits is
still incomplete [5]. Indeed, complete reliance on studies
looking at a set of finely mapped SNPs, as in GWAS,
ought to be reconsidered for future studies [30, 31].
In genomics, currently, many studies have shifted
focus to rare variants in the belief that these will help us
to better understand disease. The Department of Health
in England has also launched a company, Genomics
England, who are in the process of sequencing the
genomes of patients recruited from within the National
Health Service (NHS). The emphasis of Genomics
England is on the study of rare diseases and the contri-
bution of genomic variants to these (Genomics England,
available from: http://www.genomicsengland.co.uk
[Accessed March 4, 2017]). With the aim of sequencing
100,000 genomes, this project will undoubtedly add
much to our knowledge of rare variants and rare disease
but, as per other landmark sequencing projects, it will
equally leave us with many questions and not bring us
much closer to fully understanding disease mechanisms.
The hypothesis that rare variants even contribute greatly
to disease must be brought into question, and it has
been [32–36]. Results from recent studies infer that
complex phenotypes and diseases are in fact brought
about by a mixture of both common and rare variants,
each with different effect sizes [37–41]. Additionally, as
monogenic diseases appear to be in the minority, with
most phenotypic traits and diseases appearing to be
dictated by complex genetics, sequencing projects will
never advance our knowledge of these to a great extent
Table 1 breast cancer CCND1 locus. Status: unsolved
In breast cancer, germline SNPs at 11q13 in the vicinity of CCND1 have
puzzled researchers for decades. Cyclin D1 (CCND1) is key to cancer
development: over-expression of CCND1 has been found in numerous
cancers, whilst repression of CCND1 impairs homologous recombination-
mediated DNA repair, making cells more sensitive to damaging agents.
From GWAS, rs614367 is one of the SNPs most associated with ER+
(oestrogen-positive) breast cancer (p = 10− 39) [187]. The only problem
with rs614367 is that it is located in a large intergenic region, upstream
of CCND1 - its function and how it alters CCND1 expression remains
unknown. A separate study then found more intergenic SNPs at 11q13
in linkage disequilibrium with the original SNP, rs614367. These newly-
identified SNPs are located within known enhancers and silencers of
CCND1: PRE1 and PRE2 (putative regulatory elements 1 and 2) [188].
Their role is thought to be in modulating the binding of the ELK4 and
GATA3 transcription factors, most likely modifying transcription of CCND1.
Conclusion: The exact mechanism is still yet to be understood.
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without thinking beyond the genome. Unfortunately, we
can neither abandon these genome sequencing efforts
because the information they provide is complementary
to everything observed elsewhere in the cell.
The transcriptome
Including knowledge of the transcriptome with that of the
genome can help to hone down the list of genomic regions
that are likely to be implicated in disease and, as we’ll see,
the transcriptome and genome are inextricably connected.
Again, in cancer, studies looking at gene expression in the
past have been very successful in both segregating cancer
into subtypes and also identifying the key oncogenic
drivers of each [42–44]; yet, despite this, these still fail to
complete our understanding of the underlying biological
mechanisms for most findings. In fact, the results from
ENCODE [7] prove to us that regulation at the level of the
transcriptome is just as complex as that at the level of the
genome, a finding echoed elsewhere in an earlier study by
Mercer et al. [45]. Indeed, the original estimate on the
number of protein coding genes upon the completion of
the Human Genome Project (HGP) was 30,000–40,000
[2], which is a reasonable estimate, but it fails to take into
account the now almost 200,000 identified transcripts and
their splice isoforms that code for a messenger RNA
(mRNA) that are either protein coding or have regulatory
potential [7]. In fact, we now realise that only a small frac-
tion —up to 2%— of the genome is actually transcribed
into mRNA and then translated into protein [5]. Surpris-
ingly, a much larger fraction —up to 70%— is transcribed
into mRNA but not translated into protein - these are the
non-coding RNAs (ncRNAs). Although for most of these
ncRNAs the function (if any) remains unknown, some
have been known for a long time, such as X-inactive spe-
cific transcript (XIST), which acts as an effector in female
chromosome X inactivation [46]. Others, such as HOX
transcript antisense RNA (HOTAIR), are strongly impli-
cated in cancer [47]. In addition, regulation at the level of
the transcriptome is intertwined with that of both itself
and the genome through ncRNA interactions [48] —in-
cluding micro-RNA (miRNA) [49], antisense RNA [50],
long intergenic non-coding RNA (lincRNA) [51–53],
etc.— and also further afield at the level of chromatin [54]
and the proteome.
One could make the argument that the complexity of
the transcriptome, in fact, far supersedes that of the gen-
ome due to the almost innumerable number of potential
RNA interactions that can occur between DNA, proteins,
and other RNA species, echoing Lander’s earlier words.
Transcription at a given locus is also quantifiable, with dif-
ferent levels of a transcript having potentially key roles in
determining pathway and cell-type lineages (e.g. Sox2,
Oct4, and Nanog) [55], and also functioning as buffers
and dictating the transcription of other RNA species, as is
seen with antisense RNA [50]. Antisense RNA transcripts
are of particular interest because they stump the long held
belief that transcription only occurs on a particular DNA
strand. As transcription factors and enhancers do not
know the rules that we believe they follow and merely
bind to wherever there is an accessible matching motif, be
it on the coding or non-coding strands, transcription on
both strands can be expected. At certain genomic regions,
transcription may even be physically ‘blocked’ when the
same gene is being transcribed concurrently on both the
sense and antisense strands as both RNA polymerases
collide [50].
Many techniques are available to begin the undoubtedly
difficult task of unravelling this transcriptomic complexity.
For example, chromatin isolation by RNA purification se-
quencing (ChIRP-seq) can be used to determine regions
of DNA that are bound by a RNA of interest [54], whilst
crosslinking, ligation, and sequencing of hybrids (CLASH)
[56] is capable of determining RNA-RNA binding.
RNA-protein interactions can also be determined through
multiple other techniques including RNA immunoprecipi-
tation sequencing (RIP-seq) [57–59] (further techniques
can be found in Table 2). The transcriptome is neither
static within an organism and differs across different tis-
sues and cells [8] – one could make the argument that
each cell has, in fact, a unique profile, with a ‘gradient’ of
transcription across the entire human organism’s 1 trillion
cells. The differences between each cell are brought about
by a combination of the genetic code and both epigenetic
and intrinsic and extrinsic environmental interactions,
which slightly modify the transcriptional programme from
one cell to the next in a gradient-like fashion.
Chromatin structure and folding
The transcriptome and its innumerable potential interac-
tions operate within the spatiotemporal confines of
densely-packed chromatin, i.e., DNA tightly wound
around histones, which is itself ever changing in relation
to cell cycle processes [60] and in preparation and re-
sponse to transcription [61, 62]. Although research at the
level of chromatin is still not a primary interest for many
research groups, we are nevertheless now beginning to
better appreciate the 3-dimensional structure and folding
of the DNA molecule and the role that this plays in regu-
lation and disease mechanisms. DNA ‘accessibility’ is also
key, as much of the genome remains inaccessible to the
cytosol, thus, shielding these regions ―including any
binding motifs within them― from transcription factors
and other proteins.
Mercer and Mattick provide an outstanding review of
genomic complexity, highlighting the importance of
DNA-protein interactions and ncRNAs in, literally, shap-
ing the genome and regulating gene expression in diverse
ways [63]. The ability to capture the 3-dimensional
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structure of a portion of chromatin can be achieved
through chromosome conformation capture (3C) technol-
ogy [64] - other, more complex, ways of interrogating
chromatin and its interactions, including chromosome
conformation capture on chip (4C), chromosome con-
formation capture carbon copy (5C), and high-throughput
chromosome conformation capture (Hi-C), are mentioned
in Table 2. Achieving this genome-wide to produce a
‘structural reference chromatin’, akin to the feats achieved
by the HGP and ENCODE for the genome and transcrip-
tome, respectively, is currently over-ambitious and poses a
major challenge [63]. Moreover, based on what we now
understand, DNA in its chromatin state is a ‘fluid’ mol-
ecule ―not ‘fixed’ and static― that is constantly altering
its structure inside the nucleus in relation to protein,
ncRNA, and environmental interactions.
The inherent genetic makeup of each individual’s gen-
ome —mainly in terms of copy number variation, SNPs,
short tandem repeats, retrotransposons, etc. — would
additionally translate to subtle variation in chromatin
structure. Trying to delineate this level of subtlety could
only be accurately predicted by entering the realm of
quantum chemistry and by shifting the view of DNA
from being a sequence of letters to that of a large, com-
plex, deoxyribonucleic molecule, as it was when it was
first discovered [65], which interacts with proteins and
other nucleic acids in the cytosol via diverse electro-
chemical and electromagnetic interactions. Such work is
currently being done in the quantum chemical and
mechanical sciences [66–68], but is currently not a pri-
mary focus of this review. In addition, although trying to
model an entire human DNA molecule in this way
would be useful, it is computationally unfeasible.
With a greater appreciation of the importance and
complexity of the genome, transcriptome, and epige-
nome, one can thus begin to imagine a very dynamic en-
vironment within the cytosol —a cellular ‘microcosm’ of
activity—, whereby transcription is a pervasive process
with transcription factors binding at numerous loci in
the genome and initiating transcription where the elec-
tromagnetic potential, i.e. ‘binding strength’, mediated via
certain DNA motifs or interactions with other proteins,
is sufficiently strong such that transcription of down-
stream targets can ultimately occur - where the binding
is not sufficiently strong, transcription of targets may be
weak or not occur at all; an environment where the ‘pil-
lars’ that give chromatin its shape and form, i.e., his-
tones, are responding to environmental stressors [69] in
a cell type-specific manner and, in this way, increasing
or decreasing the accessibility —or ‘opening up’ or
‘closing’ loops— of certain DNA regions to factors in the
cytosol, thus modifying expression profiles; finally, an
environment where chemical modification of DNA
bases, e.g., the addition of methyl groups (or
‘methylation’) is again brought about via environmental
interactions and which actively hampers the expression
of genes by, in part, reducing the binding of transcrip-
tion factors [70, 71].
The technology that has driven research
A historical perspective: C.1980s onwards
Much of the challenge for understanding the mechanisms
that drive the structure and function of nucleic acid, i.e.,
DNA and RNA, are limited by available technology.
Although we now have numerous ways of interrogating
the secrets of the genome (Table 2), automated sequencers
utilising the dideoxy-sequencing method of Sanger [72]
have been relied upon for DNA sequence information
since 1977. The first successful automated sequencing
runs utilised the Applied Biosystems (ABI) 370A and se-
quenced two cDNA clones encoding the muscarinic
cholinergic receptor and the ß-adrenergic receptor within
a rat heart cDNA library [73] - at the time, it was claimed
that one sequencer could obtain > 30,000 bases with five
overnight sequencing runs. Given the fact that the haploid
human genome is approximately 3.5 billion bases-pairs, in
1987 sequencing one human genome on 100 of these in-
struments would have taken 5000 days or 13.7 years, with
a cost of undoubtedly astronomic proportions.
Thus, whilst sequencing the cellular genome was first
discussed as early as 1984 [74] and was a chief goal of
the HGP [75], clearly no one intended to sequence an
entire human genome with the ABI 370A on a routine
basis. However, innovations ensued, detection methods
were enhanced with the advent of capillary electrophor-
esis [76] and, in 2001, with multiple high throughput
DNA sequencers (ABI 3700) running in tandem, the hu-
man genome was sequenced in two efforts [1, 2] with
roughly 90–95% genomic coverage, and in a relatively
short amount of time: 15 months [2] and 9 months [1].
These efforts provided for a momentous event in our
quest to understand DNA, colloquially referred to as
‘the code of life’, and they provided impetus to sequence
and understand DNA at an even quicker pace in the fu-
ture. Whilst saying this, the first attempt to then move
beyond ABI’s automated sequencer was not driven by ef-
forts to sequence the human genome; rather, “to discover
and understand the function and variation of genes”
[77]. The term massively parallel signature sequencing
(MPSS) was used to describe a sequencing platform that
would become the prototype for what was to follow as
we entered the twenty-first century [77]. This platform
was able to sequence millions of DNA strands at one
time in conjunction with in vitro cloning of cDNA on
microbeads. The instrument employed an innovative
system that utilised a charge-coupled device (CCD)
detector followed by image processing of fluorescent
signals corresponding to each of the 4 deoxynucleotides.
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The method harnessed biochemical and enzymatic reac-
tions to deliver short tags that were 16 to 20 bases long,
referred to as ‘signature sequences’. This approach, devel-
oped as an alternative to the highly variable probe hybri-
dising methods of microarray chips [78] was known,
previous to MPSS, as serial analysis of gene expression
(SAGE), which originally relied on short tags of 9 nucleo-
tide bases [79]. Each of these methods —MPSS, SAGE,
and the hybridisation method of arrayed cDNA libraries
(microarrays)— relied upon previous knowledge of the
mRNA sequences that code for the genes of interest.
These platforms in a strict sense were not and are not
DNA sequencers in the same way that a sequencer is de-
fined today. Thus, it was impractical to expect MPSS to
be able to carry out de novo sequencing on the genome of
biological organisms that had not yet been deciphered.
In 2005 and 2006, after years of academic research
into improved biochemical processes, two sequencing
platforms emerged: the 454 sequencer [80] and the Illu-
mina/Solexa Genome Analyzer, which both utilised se-
quencing by synthesis (SBS). This method, outlined in
Hyman [81], involves the detection of the base-by-base
addition of each of the 4 nucleotide bases facilitated by a
biochemically engineered DNA polymerase. The detec-
tion method utilised in the 454 sequencer [80] takes ad-
vantage of the release of pyrophosphate (PPi), which
occurs after the addition of each base, and then becomes
the substrate for a coupled enzymatic reaction with lu-
ciferase that results in the release of light [82]. Another
group at the University of Cambridge developed a plat-
form that involved a novel single molecule approach
with a laser detection system [83] that utilised nucleo-
tides adapted with florescent and reversible 3′ termin-
ator moieties, which in effect preserved the viability of
the growing DNA molecule as it was replicated from the
double-stranded template. This sequencing method be-
came the driving force behind the technology spawned
by engineers at Solexa, later acquired by Illumina [84]. A
similar detection method involving fluorescently-labelled
nucleotide bases was developed by a group at Columbia
University [85, 86]. At the time, several competing tech-
nologies were attempting to replace the dideoxy Sanger
sequencing method, then considered the gold standard
for DNA sequencing [87].
What was driving this profusion of technological
innovation? The goal for all of the competing technolo-
gies was to introduce a massively parallel sequencing
platform that could sequence a genome in a matter of
days instead of months. Thus, one could argue that we
have had such an intense interest in the relationship of
DNA sequence to disease due in part to the fact that the
first technological successes that came out were specific-
ally designed to read DNA sequence quickly, reminis-
cent of the series of technological advances that came
from Apollo Program. Indeed, the concept of the ‘per-
sonal genome’, which envisions a world where everyone
can have their genome sequenced for as little as $1000
[88], has propelled much of the change and innovation
that has occurred during the past 15 years. While the
technologies introduced by 454 Life Sciences in 2005
and Illumina/Solexa in 2006 demonstrated a remarkable
ability to sequence DNA at a rate that was orders of
magnitude faster than the ABI sequencers, they did not
deliver the $1000 genome.
Then, in 2008, Baylor College of Medicine reported
the sequencing of Dr. James Watson’s complete genome
with the 454 sequencing platform to a depth of 7.4-fold
[89] - it took 2 months and cost less than US$1 million.
Comparative bioinformatics revealed 3.3 million SNPs
and structural variation in Dr. Watson’s genome. Also in
2008, in a report outlining the SBS method first devel-
oped by Balasubramanian and Klenerman [83] at
Cambridge, the genome of a male Yoruba from Nigeria
was sequenced to > 30× with the Genome Analyzer
(Illumina/Solexa) [84], taking 8 weeks to complete at a
cost of US$250,000.
Modern technological advances: C.2010 onward
The utilitarian needs that serve to advance technology
often result in unanticipated discoveries that carry re-
search in new directions. Pacific Biosciences (PacBio) de-
veloped a platform based on single-molecule real-time
(SMRT) sequencing that was able to successfully sequence
very long fragments of DNA [90]. In 2010, it was recog-
nised that the SMRT technology would be able to secure
read lengths greater than 1 Kbp, which far surpassed the
capability of the SBS method at that time, i.e., 100-150 bp
(Genome Analyzer) and 330 bp (Roche 454) [87]. Soon
thereafter, the SMRT technology was utilised in a de novo
sequencing method to demonstrate its ability to sequence
the entire genome of a bacteria using only a single, long
insert shotgun DNA library [91]. The mean length of the
reads for this work was 5777 bp with a mean accuracy of
99.9%. Prior to this research conducted by Chin et al. [91],
the SMRT platform was already deemed valuable as a tool
for microbial phylogenetic profiling. The platform has in-
herent advantages over Sanger and Roche 454 for sequen-
cing the 16S ribosomal RNA (rRNA) genes within
microbial populations, which require longer reads to give
finer resolution [92]. Due to the fact that the SMRT plat-
form gives reads that are four times longer than the 454
platform and does not require a library amplification step,
the cost was at that time significantly less than other
sequencing technologies.
In addition to the recent proliferation of research
conducted in the field of microbial profiling, longer read
sequencing technologies have been utilised in attempts
to produce haplotype-resolved genome sequences, i.e.
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haplotype phasing. The need for this type of sequence
information becomes apparent when considering heredi-
tary disorders, which are invariably linked to the haplo-
type and mode of inheritance [93]. In addition to SMRT,
Oxford Nanopore Technologies (ONT) also developed a
platform that provides haplotype phasing; however, high
error rates seen in both of these platforms proved to be
a difficult hurdle to move past when it was discovered
that PCR-chimera formation was not detected by soft-
ware assembly programs [94]. An alternative approach
to increasing the read length to gain long contiguous
reads is to manipulate the upfront library preparation
with a method that assigns a molecular barcode to very
long (> 50 Kbp) DNA fragments, which are then se-
quenced with a short read NGS platform. This approach
ensures that excessive chimera formation will not take
place. After sequencing, bioinformatic algorithms assem-
ble the fragments into a haplotype-resolved genomic se-
quence, e.g., 10× sequencing (10× Genomics, Pleasanton,
USA). This method (from c.2015), along with single cell
DNA and RNA sequencing, represents the current state
of the art in terms of technological advances in sequen-
cing since the HGP in 2000, and involves the attachment
of several million synthetic barcodes —each to one DNA
fragment within the genome of interest—, which can then
furnish a de novo assembly of any genome and inciden-
tally provide the haplotype phasing of that genome [95].
Regarding the role of PCR and NGS, it is important to
grasp that, for most if not all sequencing methods, DNA
amplification is a necessary preliminary step in order to
increase the detection signal, whether that signal will
originate from the excitation of a fluorescently labelled
molecule (e.g. SBS), emitted light resulting from an en-
zymatic reaction (e.g. via PPi release), or the disruption
of an electrical current (e.g. ONT). However, PCR-driven
amplification will result in artefacts such as chimera for-
mation, mentioned above, as well as random base modi-
fication errors [96]. To overcome base errors, NGS
methods are designed to sequence at great depths of
coverage to ensure that these errors —and indeed base-
calling errors due to the sequencing process itself—
can be bioinfomatically removed from the final data,
or at best reduce their influence. For example, thresholds
can be set for a minimum sequencing read depth over
each base position during variant calling to ensure that er-
rors retain less influence. On the other hand,
PCR-chimera formation cannot be entirely eliminated
from any NGS method without specific algorithms de-
signed to target each region of interest within the sequen-
cing data in order to computationally identify the
chimeric events. Of importance, however, the length of
the PCR amplicon affects the prevalence of chimera for-
mation, with shorter PCR amplicons resulting in lower
numbers of chimeric sequences. In saying this, when NGS
is utilised to gain insight into the presence of SNPs with-
out regard to how these variants relate to one another, in
terms of haplotypes, then chimeric artefacts do not pose
the same problem as when a definitive haplotype phasing
determination is the goal.
Cutting edge gene editing technology
As technological advances progressed for probing the gen-
ome and far beyond this, and as knowledge contributed
by academic settings about disease association variants
and disease biomarkers accumulated at enormous rates,
the desire to actually introduce modifications to the
‘language in which God created life’ became a goal of some
research groups, with controversy [97, 98]. Presently, the
leading gene editing system involves CRISPR (clustered
regularly interspaced short palindromic repeats)/Cas,
which has been demonstrated to cleave the genome at
endogenous loci in human and mouse cells [99], and to
facilitate chromosomal rearrangements through sequence-
specific DNA double-strand breaks (DSBs) [100] (Fig. 1).
This type of gene editing often requires that the target
sites be located on the same allele (cis) and it is crucial to
examine the entire genome for unintended off target ef-
fects in particular when gene editing is applied for clinical
applications [101]. While there have been well designed
assays to determine off target effects [102], such methods
do not directly sequence the entire genome of cells that
have undergone CRISPR gene editing. Thus, modern
technology that can produce a haplotype-resolved whole
genome has much utility in the realm of gene editing,
both pre- and post-experimentation.
Main text
Complex genetics, complex disease: Room for gene editing?
The CRISPR/Cas system has provided an unprecedented
ability to delve further into the complexity of the
genome and is a technique that is being widely discussed
Fig. 1 ‘Surgery’ by CRISPR
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across different areas, including disease control in agri-
culture (see Table 3 for oversight on CRISPR and bees),
drug manufacturing, ‘de-extinction’, vector control, food
production, and others [103]. The ability to direct the
Cas nuclease in a sequence-specific manner by simply
altering a 20 nt guide sequence has permitted a cost-ef-
fective, high-throughput way to perform genome-wide
analysis. Indeed, numerous large scale CRISPR/Cas9
knockout screens have been employed to generate
loss-of-function mutations which allow functional
characterisation of all annotated genetic elements [102,
104–108]. These screens have been implemented across
a wide range of disciplines and have identified many
promising hits, including: essential genes for cell viabil-
ity, genes that confer resistance to current drug therap-
ies, miRNAs involved in cell growth, potential cancer,
and anti-viral drug targets etc. [104, 105, 107].
However, these screens have also highlighted a major
issue, with researchers finding little correlation between
the results from CRISPR/Cas9-driven screens and those
previously carried out using techniques such as RNA
interference (RNAi) [109]. A recent CRISPR/Cas9 screen
for essential genes involved in tumour growth revealed
that the MELK protein known to be essential in tumour
growth does not drive cell proliferation in cancer cells as
previously thought [110]. As CRISPR/Cas9 and RNAi
mediate their effects by different mechanisms, it does
not seem irrational that they can yield different results,
although, drawing conclusions from contradictory re-
sults is problematic. RNAi has a well-documented ten-
dency for off-target effects [111–115]. This underlines
the need to validate results by complementary shRNA
and CRISPR/Cas9 screening approaches to produce a
more comprehensive analysis [105].
The generation of a catalytically inactive ―or ‘dead’―
Cas9 (dCas9) introduced the possibility of fusing functional
proteins to dCas9, allowing targeting in a sequence-specific
manner without initiating a double strand break [116]. This
has led to the generation of innovative adaptations of the
CRISPR system that have greatly expanded the molecular
biology toolkit and advanced both the scope and effective-
ness of genome editing. Further, an inventive strategy
termed ‘CRISPR-X’ has created a novel and rapid approach
to investigate protein function [117]. It involves fusion of
dCas9 to activation-induced cytidine deaminase (AID),
which mediates somatic cellular hypermutation (SHM).
This can be used to rapidly generate a diverse library of
mutants with improved or novel functions, which can then
be investigated. Another approach utilises the same enzyme
to achieve ‘base-editing’ [118]. This provides a novel
programmable way to directly change a mutated base at a
greater efficiency than point mutations by homology-di-
rected repair. However, as previously described, to get a full
appreciation of complex disease, we need to look beyond
the genome level. To facilitate this investigation, researchers
have now generated adaptations to the CRISPR system that
allow interrogation of both the transcriptome and
epigenome.
CRISPR and the transcriptome
Transcriptional regulation provides a powerful approach
to further the understanding of gene function and regu-
latory networks. However, the mechanism of transcrip-
tional regulation in eukaryotic cells is complex and
involves the interaction of many different transcription
factors at DNA regulatory elements that can span large
regions of DNA [119]. Previous techniques such as
RNAi have been employed to investigate transcriptional
repression but, as mentioned, they are prone to
off-target effects that can complicate the interpretation.
In addition, RNAi is limited to targeting protein coding
transcripts only, whereas CRISPR interference (CRISPRi)
involves the fusion to a repressive KRAB effector do-
main [120], thus allowing transcriptional repression be-
yond the coding sequence to include miRNAs,
lincRNAs, ncRNAs, etc. Alternatively, fusion of dCas9 to
transcriptional activation domains such as VP64 can be
used to upregulate gene expression, known as CRISPR
activation (CRISPRa) [120, 121].
Building on this initial approach, transcriptional acti-
vation in a real-life scenario was considered, whereby
transcriptional factors act in synergy with multiple
co-factors. This hypothesis resulted in a CRISPR com-
plex termed ‘Synergistic Activation Mediator’ (SAM)
[122]. SAM combines VP64 with additional activation
Table 3 Crisis ‘bee’. Status: imminent problem
In recent years, domesticated honeybees (Apis mellifera) and commercially-
reared bumblebees (Bombus terrestris) have become increasingly important
in global crop production by enhancing pollination [223], as global
agriculture faces the major challenge to maintain food security to feed an
ever-increasing human population. The challenge grows bigger by the
severe declines suffered by these pollinators due to land use change,
causing habitat loss, fragmentation, degradation and resource diversity
[224], pesticides [225], introduction of alien species for crop pollination and
honey production, causing decline on native pollinators [226], and with
these, introduction of bee pests and pathogens [227]. Despite extensive
research efforts, no single factor has been identified as the definitive cause
of bee colony decline [228, 229], and it is likely that the interaction amongst
all these factors constitutes the driver for the bee losses. At global
level, however, most managed A. mellifera colonies are infected with
the ecto-parasite mite Varroa destructor, while other important bee
pathogens (e.g. Nosema spp. and several viruses) display global distributions
[227]. This points to the significance of these parasites and pathogens in
interacting anywhere in the world with other bee colony decline factors,
thus intensifying the problem.
The arrival of the powerful gene editing tool, CRISPR [230], could aid towards
the alleviation of the situation, particularly now that we have access to
honeybee [231] and bumblebee [232] genomes. Certain bee populations
practice ‘hive hygiene’ by removing sick and infested bee larvae, and such
populations are less likely to succumb to parasite pathogens [103].
Conclusion: Identification of genes associated with the hygiene
behaviour and editing them in less hygienic populations would help
enhance health of hives globally.
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domains to further achieve higher levels of activation. The
capacity to upregulate selected genes offers vast possibil-
ities for reprogramming cellular identity in addition to un-
derstanding gene function. Furthermore, whilst wild-type
Cas9 can be utilised to implement loss-of-function
genome-wide screens, no technology was available
previously that allows large-scale gain-of-function (GOF)
screens to be conducted in a reliable and cost-effective
way. Indeed, SAM was previously utilised for
genome-scale transcriptional activation and resulted in
the identification of genes that, upon GOF, may have re-
sulted in resistance to a BRAF inhibitor [122].
CRISPR and the epigenome
The epigenome is a complex regulatory layer that acts in
concert with the underlying DNA sequence to result in
the immense array of variation that exists between cells.
The epigenome has well documented strong links to dis-
ease status, for example, in its role in imprinting disor-
ders and neurological disease [123, 124]. For many
diseases, the problems may lie within this additional
regulatory layer rather than the genomic sequence itself.
Until now, progress in the field of epigenetics has been
limited by the availability of appropriate molecular biol-
ogy techniques to investigate the functional impact of
deposition or removal of chromatin modifications [125].
Recent developments utilise dCas9 nuclease as a target-
ing domain fused to chromatin-modifying enzymes such
as Dnmt3a, Tet1, Lsd1, or Hat catalytic domain of p300
[126–128]. This introduces an innovative capability to
add or remove chromatin modifications in a site-specific
manner, providing new insight into the downstream ef-
fects on chromatin state and gene expression of specific
sequences, offering a better understanding of the role
that epigenetics plays in disease. In addition, dCas9 has
now been fused to EGFP or a combination of fluorescent
proteins which has been called CRISPRainbow [129,
130]. This provides an insightful approach to visualise
the native chromatin. The spatiotemporal organisation
and dynamics of chromatin have a direct role in the
functional output of genome function, and the ability to
track real-time in a site-specific manner will provide an-
other dimension of our understanding of the chromatin
structure. Although these advancements introduce a
new realm of possibilities for the field of epigenetics,
such as advanced cellular reprogramming and functional
studies, epigenome editing is still in very early stages.
The effect of a stably bound Cas9 nuclease may itself
affect the chromatin state and chromatin modifications,
thus complicating interpretation [125]. Indeed, although
much remains to be elucidated about the chromatin
modification network, these advances offer promising
steps in unravelling the complexity of the genome.
CRISPR in a therapeutic setting
Thus, whilst it is clear that the genome engineering
revolution is fast living up to its potential, and that the
wild-type CRISPR/Cas system, along with the
ever-growing list of adaptations, has massively expanded
our ability to investigate the genome to a new depth, two
central issues persist: specificity and delivery. For CRISPR/
Cas9 to be used in a therapeutic setting, these two issues
need to be thoroughly addressed. Off-target cleavage is a
known caveat of the CRISPR/Cas system, with many
groups reporting indels at off-target sites [131, 132]. How-
ever, it is clear that initial guide-design is absolutely critical
in achieving both good on-target cleavage in addition to
low levels of off-target cleavage [133–135]. An attempt to
rationally engineer Cas9 in order to improve the specifi-
city has led to the development of high-fidelity Cas9
(HF-Cas9), enhanced Cas9 (eCas9), and hyper-active Cas9
variant (HypaCas9) - in all cases off-target cleavage was
greatly reduced [136–138].
Furthermore, orthologues of S. pyogenes Cas9 from differ-
ent species can be considered, which recognise more intri-
cate PAMs (protospacer adjacent motifs) and thus have a
reduced number of off-target sites within the genome
[139]. Following the emergence of Cas9 for use in mamma-
lian cells, an additional Class II nuclease, Cas12a, formerly
known as Cpf1, was discovered [140]. Cas12a offers several
distinct differences compared to Cas9, such as its use of
T-rich PAMs and its generation of staggered-end double
strand breaks with 5′ overhangs. Interestingly, Cas12a has
been shown to be more specific than S. pyogenes Cas9, of-
fering a promising alternative [141, 142].
Another hurdle to overcome is the delivery of the
CRISPR/Cas system. For productive gene editing, an opti-
mal delivery vehicle should be highly specific and efficient
for a particular cell type, not produce an immune response,
exhibit minimal genotoxicity and, in order to minimise
off-target effects, the expression of the cargo should not
persist for an extended period of time. Currently, no vehicle
exists that meets all of these requirements; however, the
field of gene-editing is nascent and the potential delivery
options are continually evolving; therefore it is likely the
current limitations of delivery vehicles will be overcome.
Current strategies for delivery of CRISPR/Cas9 components
have been extensively reviewed by Glass et al. [143].
Genome editing can additionally be only implemented
in a setting where there exists a high level of under-
standing of the underlying disease mechanism. We now
focus on 3 major disease areas in which genome editing
could be applicable.
Complex genetics: A focus on 3 disease areas
Asthma
Asthma is a heterogeneous syndrome characterised by
chronic airway inflammation, airway hyperresponsiveness
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and intermittent airway obstruction that result in recur-
rent episodes of breathlessness, wheeze and cough.
Asthma is emblematic of a truly complex genetic dis-
ease thought to develop through the interaction of mul-
tiple genetic loci and environmental factors and is
estimated to affect approximately 300 million world-
wide [144]. Asthma most often debuts during early
childhood and it is currently the most common chronic
disease in childhood [145] - its heritability is estimated
to be up to 70% [146, 147].
The earliest childhood asthma disease-gene mapping
approaches, including linkage and candidate gene based
studies, had mixed results, resulting in identification of
only a handful of reproducible loci. However, the advent
of technical and statistical methods for comprehensive
GWAS has identified numerous reproducible asthma-
susceptibility loci including ORMDL3, IL1RL1, WDR36,
PDE4D, DENND1B, RAD50, IL13, IL18R1, SMAD3,
HLA-DQB1, GSDMB, IL33, IL2RB, RORA, HLA-DPA1,
IL6R, LRRC32, C11orf30, TNIP1 [146, 148–150]. More
recently, two consortia, one European (GABRIEL) [151]
and one North-American (EVE) [152], conducted inde-
pendent large-scale meta-analyses of nearly all available
asthma GWAS data, reporting striking overlap in the
abovementioned loci, which predominantly reside in
regulatory regions of the genome and are involved in im-
mune regulation, which is an integral part of asthma
pathogenesis. However, as has been observed in virtually
all complex diseases, the asthma loci identified to date
explain only a small proportion of the total observed
heritability of the disease, suggesting that novel ap-
proaches are required to identify the additional risk vari-
ants underlying this ‘missing heritability’.
The first childhood asthma GWAS identified common
regulatory variants at and near the ORMDL3/GSDMB/
ZPBP2 loci on chromosome 17q21 in three populations
of European ancestry, a finding that has now been con-
firmed in various ethnic groups. The 17q21 locus has
been shown to increase the risk for an early onset,
non-atopic phenotype through alterations of the
sphingolipid metabolisms, resulting in bronchial hyper-
responsiveness [153]. The understanding of the under-
lying biology of how this asthma locus operates will
provide an avenue for development of new asthma drugs
in the near future (see Table 4).
More recently, a genome-wide association study identi-
fied CDHR3 as a novel susceptibility locus for early child-
hood asthma with severe exacerbations [154]. The CDHR3
gene is highly expressed in airway epithelium and was, in a
subsequent study, shown to be a rhinovirus C receptor of
importance for both binding and replication of the virus
[155]. Thus, novel therapeutics targeting this specific gene
product may alleviate the burden of acute virus-induced ex-
acerbations in children with the risk variant.
Another important field in asthma genetics is pharma-
cogenomics, which is the study of the role of genetic de-
terminants in the variable, inter-individual response to
medications. Pharmacogenomic studies are of particular
interest as up to one-half of children with asthma do not
respond to treatment with inhaled β2-agonists, leukotri-
ene modifiers, or inhaled corticosteroids. There has been
numerous studies and findings, including ADRB2 [156]
and CRISPLD2, which has been shown to regulate the
anti-inflammatory effects of corticosteroids in airway
smooth muscle cells [157].
All of the above findings highlight how genetic studies in
asthma have provided important and clinically-applicable
knowledge that may be utilised by CRISPR in the future.
Ocular disorders
Ocular genetic disease offers distinct benefits as a test
bed in the field of genome engineering. A high propor-
tion of the causative genes in ocular diseases have been
elucidated and are due to a single mutation in a single
Table 4 Childhood asthma and the 17q21 locus. Status: partially
solved
Childhood asthma is the most common chronic childhood disorder with
up to 50% of all children experiencing asthma-like symptoms before the
age of 6 years, and 15% being diagnosed with persistent asthma during
school-age [233]. Asthma is considered a heterogeneous syndrome
consisting of several endophenotypes with distinct clinical features,
divergent underlying molecular causes, and different prevention and
treatment options [234]. There is a substantial genetic contribution to
asthma susceptibility and studies have revealed more than 100 implicated
genes.
Importantly, one of the first GWAS studies focusing on childhood onset
asthma discovered a risk locus at 17q21, increasing the risk of asthma by
20% [235], which has since then been robustly replicated across different
ethnicities in large meta-GWAS consortia [151, 152]. Thereafter, it was
shown that genetic risk variants in the 17q21 locus up-regulate
transcription of the ORMDL3 gene in EBV-transformed lymphoblastoid
cell lines [235] and that rs12936231 is the functional SNP, which, via
allele-specific changes in chromatin binding of the insulator protein
CTCF, is responsible for ORMDL3 expression [236]. However, the mechanistic
link between the ORMDL3 gene and asthma susceptibility was unknown.
Further studies showed that the ORMDL3 protein is expressed in airway
epithelium cells [237] and that ORMDL3 and other related orm proteins
in the endoplasmic reticulum have a major role in sphingolipid homeostasis
via inhibition of serine palmitoyltransferase (SPT), which is the rate-limiting
enzyme in de novo sphingolipid biosynthesis [238, 239]. This finding
triggered the hypothesis that the ORMDL3 gene increases the risk of
asthma through the sphingolipid metabolism [153], which has been
confirmed in mouse studies showing that decreased sphingolipid
biosynthesis in lung epithelial tissue [240] and SPT knockout [241]
associate with airway hyper-reactivity via altered levels of ceramides,
sphingosine-1-phosphate and sphingomyelins, subsequently affecting
lung magnesium homeostasis.
Conclusion: Our understanding of the underlying biology of the initial
GWAS discovery of 17q21 as a strong childhood asthma susceptibility
locus has led to the recognition that the ORMDL3 protein, the SPT
enzyme, and the sphingolipid metabolism are important players in airway
reactivity and asthma pathogenesis, which may lead to novel therapeutics
targeting this pathway. However, it is still unknown exactly how the
sphingolipid homeostasis is regulated by expression of ORMDL3 and
external environmental perturbants, but this presumably involves a
network of multiple interconnected mechanisms that can be disentangled
by metabolomics studies.
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gene [158, 159]. In addition, the eye offers unique ana-
tomical and physiological qualities that make it amen-
able to treatment; it is easily accessible, has a small
surface area and holds an immune-privileged status
making ocular diseases an ideal system in which to de-
velop CRISPR/Cas9 gene therapy [160].
Gene-therapy for recessive retinal diseases caused,
largely, by loss-of-function mutations is more advanced
than for therapies for dominant, gain-of-function dis-
eases. There are several on-going clinical trials for retinal
diseases including choroideremia, Leber congenital am-
aurosis (LCA), Retinitis pigmentosa, Usher syndrome,
and Stargardt disease [161–165]. These therapies all em-
ploy a gene-replacement strategy in which a functional
copy of the gene is introduced to target cells by either
adeno-associated virus (AAV) or lentiviral vectors.
Gene-replacement is not always a viable approach as
vector carrying capacity restricts the spectrum of disorders
that can be treated and, while lentivirus has a larger carry-
ing capacity, the potential for it to integrate into the gen-
ome raises safety concerns. A much more attractive
treatment strategy would be to correct the defect itself,
utilising the novel CRISPR technology. Editas Medicine
have a clinical trial planned for LCA in which CRISPR will
be targeted to delete a cryptic splice site and restore nor-
mal splicing. They have subsequently announced future
plans for a similar trial targeted to Usher Syndrome.
An innovative allele-specific approach emerged when
Courtney el al. [166] identified the potential to utilise a
mutation that generates a novel PAM to achieve
allele-specificity. Although this work focused on corneal
dystrophy, the technique has also been exploited for use
in retinal disease by Bakondi et al. [167]. This approach
provided a highly specific treatment strategy for certain
autosomal dominant disorders. As the CRISPR technology
develops at a rapid pace it is conceivable that soon an
array of therapeutics will materialise that will allow safe
and efficient correction of a range of genetic defects.
The future for ocular disorders looks bright and, as we
begin to understand the integral players and interactions
of complex disease, treatment strategies via genome edit-
ing technologies will become apparent. The previous opti-
misation groundwork using well characterised disease as
models will allow for a smooth translation to treatment.
Cancer
In the field of cancer, the primary issue in the future will
surround tumour heterogeneity and how this will com-
plicate treatment strategies [168]. The revelation that a
single tumour biopsy represents, in fact, multiple dis-
tinct tumour cell populations [169] was a pivotal mo-
ment in the field of cancer research. Since the discovery,
a variety of studies have additionally confirmed that
metastases from the primary tumour are invariably
representative of only one or more sub-populations
[170]. The concept of clonal evolution in cancer has
been around since 1976 [171] and has been adopted in
the field in order to explain these recent findings [172,
173]. This comes as a startling realisation when one con-
siders the implications for personalised medicine: whilst
we may be capable of identifying a metastatic clone with
a key driver mutation and eradicating this with a specific
drug or therapy (if available), in the situation where the
primary tumour is highly heterogeneous, by eradicating
the initial metastatic clone we may be merely paving the
way for a different clone to rise up, which may necessi-
tate an entirely different treatment strategy [168, 172].
Thus, tumour heterogeneity and the driver of this, gen-
omic instability, have been other key focuses of research
and will continue to be.
Identification and functional validation of such driver
mutations amongst the large number of passenger muta-
tions is thus an ongoing challenge. Genome editing tech-
nology such as CRISPR/Cas9 is going some way to
address these challenges. It is now possible to reproduce
the complex genome states observed in human tumours,
such as translocations and inversions, as well as point
mutations and deletions, in both cell lines and mouse
models. Until recently, cancer mouse models were both
laboriously slow and costly to generate, requiring the in-
jection of genetically modified embryonic stem cells into
blastocytes. CRISPR has enabled the generation of
knockout and knock-in mouse models in as little as four
weeks, developing both germline and somatic mutation
mouse models.
Taking breast cancer as just one example, CRISPR has
facilitated the discovery of point mutations conferring
endocrine therapy resistance and, in doing so, has en-
abled researchers to understand the mechanism by
which this happens [174]. Further, CRISPR-engineered
mouse models have been used to identify the secondary
mutations that confer resistance to PARP inhibitors in
BRCA1 and BRCA2 mutant cancers, which are initially
responsive [175]. Others have shown that in a HER2
positive model, a CRIPSR-induced mutation within an
amplified HER2 region instead confers a dominant nega-
tive effect, resulting in cell growth inhibition via the
MAPK/ERK axis, with no effect on HER2 protein levels
[176]. That this response is potentiated by PARP inhib-
ition, and is a distinct pathway from current HER2 ther-
apies like Trastuzumab, gives some idea of the potential
of CRISPR-mediated engineering in identifying new tar-
gets for therapy. However, whilst cancer research has
been catapulted by the discovery of CRISPR, the reality
remains that delivery of Cas9 continues to be a signifi-
cant obstacle in both the generation of cancer mouse
models and the delivery of therapeutic Cas9 guide RNA
systems to treat cancer.
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Another potential application of CRISPR in cancer could
be as a companion technology to ‘blood biopsy’ based
methods. The release of circulating free DNA (cfDNA)
from tumour cells, i.e., circulating tumour DNA (ctDNA),
can be a consequence of different physiological and patho-
logical process such as apoptosis, necrosis, or active secre-
tion (Fig. 2). In cancer patients, the released DNA may
carry specific alterations within the fragment such as gen-
etic and/or epigenetic modifications, which include methy-
lation, loss of heterozygosity (LOH), and tumour-specific
mutations in oncogenes and tumour suppressor genes
[177]. In this regard, cfDNA from the blood of cancer pa-
tients ―and also circulating tumour cells (CTCs)― could
be exploited for not just diagnosis and prognosis [178, 179]
but also help to identify targets for CRISPR-mediated treat-
ment of the primary tumour. After CRISPR therapeutic
intervention, cfDNA analysis could equally be used to
monitor the effectiveness of the therapy, as it has been doc-
umented that, post-surgery, cfDNA and miRNA levels de-
crease to those found in healthy individuals [180, 181];
however, when the levels of cfDNA do not change, it might
show that residual tumour cells exist [182].
Conclusions
Our desire to achieve a greater understanding of the
genome in the past 3 decades has been the main driver
of technological development in this area. Now that we
have achieved a greater understanding, we are realising
that the genome is not the end of the line, in terms of
understanding disease. In fact, one could argue that sim-
ply understanding DNA has opened a Pandora’s Box and
that the real work has only just begun. Thankfully, the
technological advances that have allowed us to under-
stand the genome have indirectly given us opportunities
to study beyond the genome, specifically at the tran-
scriptome and epigenome (see Table 2 for a list of these),
and further beyond these.
One striking revelation from the deluge of data that
has already been produced in the biomedical sciences is
that it points out just how much we don’t yet under-
stand about disease and how much work there is still to
Fig. 2 Is there utility for CRISPR via circulating tumour DNA detection?
Table 5 Cardiovascular disease and gene editing. Status: gene
editing’s clinical utility in the cardiovascular realm
Cardiovascular disease (CVD) consists of acute coronary syndrome (ACS),
acute myocardial infarction (AMI), angina, arrhythmia, atherosclerosis,
congestive heart failure (CHF), coronary artery disease (CAD), myocardial
ischemia, etc. In the USA, per year, approximately 700,000 people suffer
their first AMI and 500,000 experience a second or recurrent AMI, with
1.7 million being hospitalised annually due to ACS [242]. Clinical
laboratories play a vital role in detecting and characterising risk of
cardiovascular diseases and there is already a gambit of tests available
for this purpose. For example, cardiac troponin is an important test for
detecting myocardial injury, whilst B-type natriuretic peptide (BNP) and
N-terminal portion of proBNP are used to detect CHF and risk for an
acute event. Numerous other biomarkers are used to monitor various
cardiovascular conditions.
However, not all biochemical tests are accurate. For example, it is known
that half of AMIs occur in individuals with normal lipid panels [242].
The lipid panel (total, LDL, and HDL cholesterol, as well as triglycerides)
—in addition to apolipoproteins (ApoA1 and ApoB), Lp(a), hsCRP,
homocysteine, and Lp-pla2— are used to manage and monitor CHD.
These tests can all be run using commercially-available reagents on various
biochemical analysers, some of which may provide inaccurate results,
possibly due to the complexity and stability of lipid molecules [243].
To improve the quality of results, alternative and more accurate methods
have been developed to measure subclasses of HDL and LDL, such as: 1,
β-quantification method [244], i.e., the reference method according to The
U.S. National Cholesterol Education Program (NCEP); 2, gradient gel
electrophoresis (GGE) [245, 246]; 3, vertical auto profile (VAP) [247];
4, nuclear magnetic resonance spectroscopy (NMR) [245]; 5, ion mobility
(IM) [248]; 6, high performance liquid chromatography (HPLC) [245].
Advances in the management of patients with cardiovascular disease
through improved pharmacologic therapy have lessened impact; however,
various limitations including patient compliance, side effects, and the need
for repeat procedures keep patients in symptomatic status [249]. Gene and
stem cell therapies in conjunction have shown promise in animal models
of myocardial ischemia [249]. CRISPR/Cas9 gene editing of the loss-
of-function proprotein convertase subtilisin/kexin type 9 (PCSK9) has also
proven to reduce LDL cholesterol levels and protect against cardiovascular
disease [250]. The major advantage of gene therapy is that, in a single
administration, permanent benefits can be obtained, and with the advent
of molecular research, further genes associated with lipoproteins and CVD
risk have been discovered, e.g. APOA1, APOA5, APOE, CETP, GALNT2, LIPC,
LPL, and MLXIPL [251], which may prove future targets of gene therapies.
Current gene therapy clinical trials have proven short-term safety; however,
long term surveillance over a period of decades is still under investigation.
Also, the cost-effectiveness of gene therapy has to be considered due to
the laborious nature of the procedures. Current pharmacological approaches
may still be more favourable in terms of cost benefit ratio [249], albeit in
terms of cardiovascular disease treatment.
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be done. Indeed, biological data is complex, having di-
verse internal structures that scientists have struggled to
interpret using traditional methods and approaches
[183], and whereas we are attempting to define how life
within the cell functions in a relatively short space of
time in order to better understand disease, life itself has
had millions of years for various processes to diversify
and become ‘fixed’, which has given us the wide diversity
of life that we now see. The main players in this diversity
are the genome, transcriptome, epigenome, and environ-
ment, with the amount of possible configurations be-
tween these being limitless.
Many diseases are therefore complex because life itself
is complex, and we are still waiting to see major improve-
ments in healthcare in the era of ‘big data’ that modern
technology has allowed us to produce [184–186]. We
don’t claim that a complete understanding of life within
the cell will help us to eradicate disease - we may under-
stand disease much better but people will still age and
develop illness. In cardiovascular disease, for example, a
vast array of methods already exist and we are already
knowledgeable on how to prevent these diseases from
occurring (see Table 5) - would adding knowledge from
the genome significantly reduce cardiovascular deaths?
In order to see significant improvement in healthcare
utilising genomic, transcriptomic, and epigenomics data,
there must be greater interdisciplinary cross talk
between scientists. This includes, but is not limited to,
physicians, clinical geneticists, computational biologists,
and policy makers. New and recent technology can help
to improve treatment, but only in the context of an
understanding of disease mechanisms. We must minimise
scenarios in which uncertainty enters the healthcare
market, particularly in relation to critical techniques such
as gene editing. Would it be feasible to excise a ‘disease
allele’ if the exact mechanism of functioning of the allele
in question was misunderstood? There is hope in terms of
data science: integrating omics data can assist in fully
defining disease mechanisms (see Table 6), which opens
up the door to ‘safe’ gene editing.
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sequencing; TIF-seq: Transcript Isoform Sequencing; TN-seq: Transposon
Table 6 T-cell acute lymphoblastic leukaemia. Status: solved
In T-cell acute lymphoblastic leukaemia (T-ALL), 25% of cases exhibit high
expression of the TAL1 oncogene, which is due to a large deletion occurring
at 1q33 that brings the coding sequences of TAL1 (a transcription factor) in
proximity to the promoter of STIL, a ubiquitously-expressed gene. This results
in the ubiquitous/over- expression of TAL1 and drives cancer. In many cases
of T-ALL, however, overexpression of TAL1 is observed without the
large deletion – in these cases, H3K27ac binding (a marker of an enhancer
region) is also found upstream of TAL1. Despite this information, the exact
mechanism of disease had remained elusive for many years in these cases.
Mansour and colleagues [252] observed these cases and found small
heterozygous insertion variants of varying lengths in the same region as
the previously found H3K27ac marks. The insertion variants, they found,
were introducing new binding sites for the MYB transcription factor family,
resulting in the over-expression of TAL1 and the driving of cancer.
Conclusion: The Mansour study shows how data from DNA, RNA, and
DNA-binding interactions can be used in combination to clearly define
a disease mechanism. In this example, observing the intergenic upstream
insertion variants (DNA), the heightened expression of TAL1 (RNA), or the
acetylation marks (DNA-binding interactions) alone would not explain the
mechanism of disease. The Mansour study, however, although difficult and
summing up years of work and studies, was made relatively easier by the
fact that only a single gene was involved: TAL1. Thus, technically, no expert
analytics or bioinformatics input was required. However, for complex
diseases like most other cancers, cardiovascular diseases, etc., describing
disease mechanisms is made extremely difficult by the fact that
there can be any number of variants —be they SNPs, insertions, deletions,
translocations, or copy number variants— involved in augmenting risk of
the disease, with none on their own contributing a large amount to the
disease phenotype. Thus, for complex diseases, there is much room for
computational methods to be introduced in order to assist in clearly
defining diseases mechanisms, but it involves a greater appreciation away
from solely the genome.
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sequencing; TRAP-seq: Translating Ribosome Affinity Purification sequencing;
TSS: Transcription start site; US NCEP: US National Cholesterol Education
Program; VAP: Vertical auto profile; vCJD: Variant Creutzfeldt-Jakob Disease;
XIST: X-Inactive Specific Transcript
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